Inhibikase Therapeutics
IKT
IKT
24 hedge funds and large institutions have $2.78M invested in Inhibikase Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Holders
24
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$140K | |
| 2 | +$22K | |
| 3 | +$18K | |
| 4 |
Millennium Management
New York
|
+$14K |
| 5 |
SG
StoneX Group
New York
|
+$12.1K |
Top Sellers
| 1 | -$299K | |
| 2 | -$88.1K | |
| 3 | -$9.58K | |
| 4 |
SC
Shay Capital
New York
|
-$8K |
| 5 |
RPCONE
Retirement Planning Company of New England
Warwick,
Rhode Island
|
-$4.97K |